Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Intervention éducative dans les 18 premiers mois de la vie pour prévenir/gérer l'obésité des enfants après un diabète gestationnel

29 septembre 2026 mis à jour par: Rita A. Gomez Diaz, Instituto Mexicano del Seguro Social

Effet d'une intervention éducative pour la prévention et la gestion du surpoids et de l'obésité au cours des 18 premiers mois de la vie Enfants et mères atteints de diabète gestationnel en assuré de l'Instituto Mexicano Del Seguro Social.

In order to evaluate the effect of an educational intervention on mothers with gestational diabetes and their offspring in the first 18 months of life, The intervention will be applied to mothers with gestational diabetes, and a group of mothers without diabetes, against a control group with the normal post-partum treatment. Effects on overweight and obesity will be evaluated in both mothers and offspring.

Aperçu de l'étude

Statut

Actif, ne recrute pas

Les conditions

Intervention / Traitement

Description détaillée

Effect of an education intervention for the prevention and management of overweight and obesity during the first 18 months of life of offspring and mother with gestational diabetes among insured of the Instituto Mexicano del Seguro Social.

ABSTRACT BACKGROUND: According to ENSANUT 2012, 9.7% of children <5 years already are overweight or obese. Recently, an increase was reported in the frequency of overweight and obesity worldwide, beginning at earlier ages, especially in Mexico. The predisposition to chronic diseases in adults may be programmed in the womb ("fetal programming"). Also, women that suffer diabetes during pregnancy have a very high risk (6.4 times more) of developing diabetes in a middle range. The challenge for health personnel dedicated to the care of mother-child pairs is to achieve glycemic control from conception and to identify all the maternal-fetal secondary complications. To carry out compliance with adherence to medical management and/or healthy eating habits would allow us to reduce future overweight, obesity and the incidence of type 2 diabetes in mother-child pairs. Approaching the mother-child pair is a great opportunity to study the intervention, which would allow us not only have a new, useful awareness in the evaluation of educational strategies, but also to apply good practices of healthy habits for the prevention of obesity and to avoid progression to diabetes. For the aforementioned reasons, the objective is: to implement and evaluate the effect of an education intervention for the prevention and management of overweight and obesity during the first 18 months of life of child and in mothers with and without gestational diabetes in insured members of the Instituto Mexicano del Seguro Social.

MATERIAL AND METHODS. Pregnant women will be invited to participate, who receive their prenatal and/or birth care in the Unidad Médica de Alta Especialidad (UMAE) Gineco-Obstretric Hospital No. 4 (HGO #4) and UMAE HGO #3 of Centro Médico "La Raza" of IMSS. After acceptance and signing an informed consent to participate in the study, 645 mother-child pairs will be included, with and without gestational diabetes mellitus (GDM), which will be diagnosed according to the criteria of the American Diabetes Association; all mothers with be between 18 and 40 years old. There will be 3 groups of binomials: 1) with GDM, 2) without GDM who will received the education intervention, and 3) without GDM who will receive the conventional care IMSS offers to mothers and nursing infants, during the first 18 months post-partum.

At the time of canalization before delivery or cesarean, a blood sample (15 mL) will be taken from the mother for measurement of glucose, glucosylated hemoglobin (A1c) and lipid profile. After birth, blood (15 mL) will be extracted directly from the umbilical cord for measurement of the child's glucose and lipid profile. Once the pediatric doctor has carried out reanimation of the newborn, previously-standardized health staff will take anthropometric measurements. During the 18 months of follow-up from birth, the mother-child pair will be given appointments at 0, 1, 2, 3, 6, 9, 12, 15 and 18 months, in which health care personnel involved in the study (nutritionist, social worker, pediatrician and family doctor) will perform activities to promote health and prevent disease, directed towards the mother-child pair and planned within the education intervention strategy based on the First 1000 Days program, or the conventional care that mothers and nursing infants receive in IMSS, according to the study group. Weekly, the mothers will be sent, by digital media and social networks, educational material to promote healthy diet and physical activity; for the child material will include the promotion of exclusive breastfeeding until 6 months, at which time promotion will be of adequate complementary foods, in addition to early stimulation activities; educational material will be handed out: posters and brochures will serve to reinforce and remind of the information given during appointments. Also, characteristics of the diet consumed by mother and child will be recorded monthly, along with the physical activity performed by the mother.

The education intervention has as objective the acquiring of knowledge, motivation, creation of an awareness of disease, adoption of healthy diet and physical activity; its components will be individual sessions, group sessions, electronic messages, etc.

SAMPLE SIZE: The sample size necessary, with a 95% confidence interval and a power of 80%, is 645 mother-child pairs, among which 215 mother-child pairs will be included with mothers who presented gestational diabetes and will receive the education intervention, and 430 pairs without gestational diabetes (215 pairs with the education intervention and 215 with conventional care).

STATISTICAL ANALYSIS: Anthropometric and biochemical data will be described using mean and standard deviation for continuous variables, or percentages for nominal or ordinal variables. The difference between variables of offspring of mothers with and without GDM, as well as the difference between groups with and without education intervention, will be analyzed with Mann-Whitney U test, Student t test, or chi square, as appropriate. Multivariate analysis will be performed, using lineal regression in models of repeated measures, to evaluate the association between 1) child weight-for-age (in Z score), and 2) mother's BMI, and the education intervention or having presented GDM or no, according to the independent variable, or the exposure that is being analyzed (effect of GDM or effect of the intervention), controlling for possible confounding variables. Values of p<0.05 will be considered statistically significant.

EXPECTED RESULTS: The education intervention was standardized in Boston, Mass, and will be implemented with the adaptation necessary for our population, in order to evaluate if it is better than the conventional treatment, for transference to the Family Medicine Units and second-level hospitals that have Gineco-obstetric services in the IMSS.

Included will be surveys on the opinion of doctors and participants to measure the acceptability of the intervention.

Expected results are: differences associated with the intervention in: a) body mass index and weight-for-age, respectively, in the mother-child pair; b) speed of growth and growth percentile score; as well as c) implementation of an education strategy that can be used as part of the care the mother-child pair receives.

DELIVERABLE PRODUCTS: Situational analysis of the mother-child pair, from the clinical point of view, laboratory studies, databases, plan for implementation of this strategy in IMSS. In addition, there will be databases that can be used for other analyses. DNA banks are contemplated, from serum and plasma, for scientific questions derived from this study.

SOCIAL IMPACT: This study will offer a model that can be implemented in all hospitals of IMSS that attend to births and/or cesareans. This will contribute to the timely prevention of obesity in insured families of IMSS, with an eye towards making it extend both at the national level for IMSS and for other health institutions. It is hoped that the education strategy will be a tool that allows a reduction in the frequency of overweight, obesity, and diabetes mellitus in our country.

DURATION OF THE STUDY: 5 years.

Type d'étude

Interventionnel

Inscription (Estimé)

645

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

      • Mexico City, Mexique, 06720
        • Hospital Gineco-Obstetrico #4

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans à 40 ans (Adulte)

Accepte les volontaires sains

Oui

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • 18-40 years old
  • insured by IMSS
  • with or without gestational diabetes

Exclusion Criteria:

  • History of type 1 or 2 diabetes, MODY or secondary diabetes
  • CKD, hepatic or cardiac disease, pregnancy hypertension, corioamniotis orpremature membrane rupture, pulmonary maturity 24 hours before birth, severe complications

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: La prévention
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Seul

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Gestational diabetes intervention

All mothers with gestational diabetes will receive 18 months of educational intervention post-partum. They and their offspring will be evaluated at months 1,2,3,6,9,12,15,and 18.

Monthly 45-minute sessions will be held, including dietary, and physical activity modification, early stimulation, exclusive breastfeeding for 6 months and the proper introduction of foods, and other support for the mother. The sessions will be supported by personalized contact by WhatsApp and programmed telephone calls, in addition to conventional treatment.

Conventional treatment includes some early stimulation, monthly visits for height/weight measurement of the offspring.

Expérimental: No diabetes intervention

Mothers without gestational diabetes will receive 18 months of educational intervention post-partum. They and their offspring will be evaluated at months 1,2,3,6,9,12,15,and 18.

Monthly 45-minute sessions will be held, including dietary, and physical activity modification, early stimulation, exclusive breastfeeding for 6 months and the proper introduction of foods, and other support for the mother. The sessions will be supported by personalized contact by WhatsApp and programmed telephone calls, in addition to conventional treatment.

Conventional treatment includes some early stimulation, monthly visits for height/weight measurement of the offspring.

Comparateur actif: No diabetes no intervention

Mothers without gestational diabetes will receive the conventional care for 18 months post-partum. They and their offspring will be evaluated at months 1,2,3,6,9,12,15,and 18.

Conventional treatment includes some early stimulation, monthly visits for height/weight measurement of the offspring.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Prevention of overweight/obesity in offspring, determined by z-score in the indicator for weight for age
Délai: 18 months

Offspring will be expected to have a difference of at least 0,3 standard deviations in z-score of the indicator for weight for age, as measured by weight on a standard weight scale over the course of the study, and compared with WHO growth charts.

18 months
Prevention of overweight/obesity mothers, determined by loss in body mass index (BMI)
Délai: 18 months

Mothers will be expected to have a loss of at least 1.8kg/m2 of body mass index (BMI, weight/height squared), as measured by weight, as measured by a standard weight scale, divided by height in meters squared over the course of the study.

18 months

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Changes in blood concentration of glucose: GDM
Délai: 18 months

Compare blood measurements of glucose of the mother over the 18 months of mothers with vs without gestational diabetes (GDM).

18 months
Changes in blood concentration of glucose: intervention
Délai: 18 months

Compare blood measurements of glucose of the mother over the 18 months of mothers with vs without educational intervention.

.

18 months
Changes in blood concentration of glycosylated hemoglobin: GDM
Délai: 18 months

Compare blood measurements of glycosylated hemoglobin (HbA1c) of the mother over the 18 months of mothers with vs without gestational diabetes.

.

18 months
Changes in blood concentration of glycosylated hemoglobin: intervention
Délai: 18 months

Compare blood measurements of glycosylated hemoglobin (HbA1c) of the mother over the 18 months of mothers with vs without educational intervention.

.

18 months
Changes in blood concentration of lipids: GDM
Délai: 18 months

Compare blood measurements of lipid profile (total cholesterol, HDL-cholesterol, LDL-cholesterol, triglycerides) of the mother over the 18 months of mothers with vs without gestational diabetes.

.

18 months
Changes in blood concentration of lipids: intervention
Délai: 18 months

Compare blood measurements of lipid profile (total cholesterol, HDL-cholesterol, LDL-cholesterol, triglycerides) of the mother over the 18 months of mothers with vs without educational intervention.

.

18 months

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Collaborateurs

Les enquêteurs

  • Chaise d'étude: Cesar R Gonzalez Bonilla, PhD, Secretary of Health

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

25 août 2020

Achèvement primaire (Estimé)

30 septembre 2027

Achèvement de l'étude (Estimé)

30 septembre 2027

Dates d'inscription aux études

Première soumission

17 juillet 2020

Première soumission répondant aux critères de contrôle qualité

28 juillet 2020

Première publication (Réel)

30 juillet 2020

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

2 octobre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

29 septembre 2026

Dernière vérification

1 septembre 2026

Plus d'information

Termes liés à cette étude

Autres numéros d'identification d'étude

  • R2018-785-079

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Description du régime IPD

Research will be shared upon written request.

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .